AstraZeneca strikes $40 million AI drug discovery deal with insitro

AstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partnership involves a $40 million upfront payment and potential milestones totaling approximately $1.46 billion. Insitro will utilize its AI platform to identify biological drivers for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Following this, AstraZeneca will manage clinical trials and further development. This collaboration signifies insitro's growing presence in the pharmaceutical industry.